Digirad Corporation Reports Second Quarter and Six-Month

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Digirad Corporation Reports Second Quarter and Six-Month Financial Results

SUWANEE, GA--(Marketwired - Aug 1, 2013) - Digirad Corporation ( NASDAQ : DRAD ) today reported revenue of $12.9 million for the second quarter, a narrowing loss and an ending cash, cash equivalents and available-for-sale securities balance of $22.2 million.

Digirad President and CEO Matt Molchan said, "Revenues in both DIS and Diagnostic Imaging businesses were up in the second quarter compared to the prior year. Camera sales, especially ergo™ and Cardius™ imaging technologies saw improvements in the period. Progress on the bottom line was also notable as the GAAP net loss was cut to $616,000 -- in a quarter that included more than $600,000 in non-recurring restructuring costs and more than $500,000 in costs associated with a proxy battle and related litigation. We were also able to aggressively return cash to our shareholders by using $3 million of cash to buy over 1.2 million of our own shares."

Second Quarter 2013 Summary

  • Total revenue for the second quarter of 2013 was $12.9 million, compared to $12.7 million for the same period in the prior year. DIS revenue for the second quarter of 2013 was $9.5 million, compared to $9.4 million for the same period of the prior year, and Diagnostic Imaging revenue for the second quarter of 2013 was $3.4 million, compared to $3.3 million for the same period of the prior year.
  • Gross profit for the second quarter of 2013 was $3.8 million, or 29.4 percent of revenue, compared to $3.7 million, or 29.0 percent of revenue in the prior year quarter.
  • Net loss for the second quarter of 2013 was $616,000, or $0.03 loss per share, compared to a net loss of $891,000, or $0.05 loss per share, in the same period of the prior year. Adjusted net loss for the 2013 second quarter, excluding the $610,000 in expenses incurred for nonrecurring items related to restructuring activities, was $6,000, or $0.00 loss per share on an adjusted basis.
  • Operating expenses for the second quarter of 2013 were $4.4 million, compared to $4.6 million in the same period in the prior year. Adjusted operating expenses for the second quarter of 2013 were $3.8 million, compared to the $4.6 million in the same period of the prior year. In addition to the restructuring costs, operating expenses for the 2013 second quarter included approximately $538,000 in costs related to a successful proxy contest and subsequent on-going litigation with a dissident shareholder group.
  • Cash, cash equivalents and available-for-sale securities totaled $22.2 million as of June 30, 2013, reflecting the use of $3.0 million in cash during the quarter ended June 30, 2013 for the Company's share repurchase program. Cash, cash equivalents and available-for-sale securities totaled $27.2 million as of December 31, 2012.

Six-Month 2013 Summary

  • Total revenue for the first six months of 2013 was $24.4 million, compared to $25.7 million for the same period in the prior year. DIS revenue for the first six months of 2013 was $18.4 million, compared to $18.7 million for the same period of the prior year. Diagnostic Imaging revenue for the first six months of 2013 was $6.0 million, compared to $7.0 million for the same period of the prior year.
  • Gross profit for the first six months of 2013 was $6.6 million, or 27.1 percent of revenue, compared to $7.4 million, or 28.6 percent of revenue in the same period of the prior year.
  • Net loss for the first six months of 2013 was $3.0 million, or $0.16 loss per share, compared to a net loss of $2.2 million, or $0.11 loss per share, in the same period of the prior year. Adjusted net loss for the first six months of 2013, excluding the $1.6 million in expenses incurred for nonrecurring items related to restructuring activities, was $1.4 million, or $0.07 loss per share on an adjusted basis.
  • Operating expenses for the first six months of 2013 were $9.7 million, including restructuring and proxy contest and litigation costs, compared to $9.5 million in the same period in the prior year. Adjusted operating expenses for the first six months of 2013 were $8.0 million, compared to the $9.5 million in the same period of the prior year, which reflects the restructuring expenses incurred since the February 28, 2013 restructuring announcement. In addition to the restructuring costs, operating expenses for the first six months of 2013 included approximately $671,000 in costs related to the proxy contest and subsequent on-going litigation with the dissident shareholder group.

Molchan continued, "Our progress internally and in the marketplace during the second quarter was solid. We continue to identify and pursue a growing number of potential 'tuck-in' acquisition targets in key DIS regions. The entire team is focused on right sizing the cost structure around our current revenue levels in order to reach profitability, and at the same time, executing both organic and acquisitive aspects of our new strategy. Remembering that we just announced our restructuring plan on February 28, I am very pleased with the progress so far. We are still deploying other components of our restructuring plan that will result in further savings, and anticipate that the vast majority of the restructuring will be complete by the end of the third quarter leading to improved net income and cash flow on a go forward basis."

Conference Call Information A conference call is scheduled for 11:00 a.m. EDT today to discuss the results and management's outlook. The call may be accessed by dialing 877-941-8418 five minutes prior to the scheduled start time and referencing Digirad. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at www.digirad.com ; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.

Use of Non-GAAP Financial Measures by Digirad Corporation This Digirad news release presents the non-GAAP financial measures "adjusted operating expenses," "adjusted net loss" and "adjusted net loss per share." The most directly comparable measure for these non-GAAP financial measures are operating expenses, net loss and net loss per share. The company has included below unaudited adjusted financial information for the quarter and six months ended June 30, 2013, which present the Company's results of operations after excluding restructuring charges. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding Digirad's financial condition and results of operations is included as Exhibit 99.2 to Digirad's report on Form 8-K filed with the Securities and Exchange Commission on August 1, 2013.

Forward-Looking Statements This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding the Company's ability to deliver value to customers, the Company's ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with changes in business conditions, technology, customers' business conditions, reimbursement, radiopharmaceutical shortages, economic outlook, operational policy or structure, acceptance and use of Digirad's camera systems and services, reliability, recalls, analysis of potential impairment and restructuring charges, the conclusion of our audit and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.

(Financial tables follow)

 
 
 
Digirad Corporation
 Condensed Consolidated Statements of Loss
(Unaudited)
 
    Three Months Ended June 30,     Six Months Ended June 30,  
(in thousands, except per share amounts)   2013     2012     2013     2012  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
Revenues:                                
  DIS   $ 9,475     $ 9,377     $ 18,414     $ 18,666  
  Diagnostic Imaging     3,415       3,333       6,022       7,014  
    Total revenues     12,890       12,710       24,436       25,680  
Cost of revenues:                                
  DIS     7,179       6,908       14,004       13,885  
  Diagnostic Imaging     1,918       2,121       3,822       4,442  
    Total cost of revenues     9,097       9,029       17,826       18,327  
                                 
Gross profit     3,793       3,681       6,610       7,353  
  Operating expenses:                                
  Research and development     177       1,047       996       1,943  
  Marketing and sales     1,009       1,671       2,245       3,387  
  General and administrative     2,571       1,811       4,673       4,075  
  Amortization of intangible assets     58       58       123       136  
  Restructuring charges     610       --       1,614       --  
Total operating expenses     4,425       4,587       9,651       9,541  
                                 
Loss from operations     (632 )     (906 )     (3,041 )     (2,188 )
Other income (expense):                                
  Interest income     16       28       39       54  
  Interest expense     (4 )     (1 )     (5 )     (1 )
  Other expense     4       (12 )     (28 )     (24 )
Total other income (expense)     16       15       6       29  
Net loss   $ (616 )   $ (891 )   $ (3,035 )   $ (2,159 )
                                 
Net loss per common share - basic and diluted   $ (0.03 )   $ (0.05 )   $ (0.16 )   $ (0.11 )
                                 
Weighted average shares outstanding - basic and diluted     19,032       19,315       19,177       19,278  
                                 
                                 
                                 
Digirad Corporation
Adjusted Financial Information
(Unaudited)
 
Adjusted Financial Data:                        
    Three Months Ended June 30,     Six Months Ended June 30,  
(in thousands, except per share amounts)   2013     2012     2013     2012  
                                 
Total operating expenses   $ 4,425     $ 4,587     $ 9,651     $ 9,541  
                                 
  Restructuring charges (1)     610       -       1,614       -  
                                 
Adjusted operating expenses (2)   $ 3,815     $ 4,587     $ 8,037     $ 9,541  
                                 
Net loss   $ (616 )   $ (891 )   $ (3,035 )   $ (2,159 )
                                 
  Restructuring charges (1)     610       -       1,614       -  
                                 
Adjusted net loss (2)   $ (6 )   $ (891 )   $ (1,421 )   $ (2,159 )
                                 
Net loss per common share - basic and diluted   $ (0.03 )   $ (0.05 )   $ (0.16 )   $ (0.11 )
                                 
Adjusted net loss per common share - basic and diluted (2)   $ -     $ (0.05 )   $ (0.07 )   $ (0.11 )
                                 
Weighted average shares outstanding - basic and diluted     19,032       19,315       19,177       19,278  
                                 
                                 
    Three Months Ended                  
(in thousands, except per share amounts)   June 30, 2013     March 31, 2013                  
                                 
Total operating expenses   $ 4,425     $ 5,226                  
                                 
  Restructuring charges (1)     610       1,004                  
                                 
Adjusted operating expenses (2)   $ 3,815     $ 4,222                  
                                 
Net loss   $ (616 )   $ (2,419 )                
                                 
  Restructuring charges (1)     610       1,004                  
                                 
Adjusted net loss (2)   $ (6 )   $ (1,415 )                
                                 
Net loss per common share - basic and diluted   $ (0.03 )   $ (0.13 )                
                                 
Adjusted net loss per common share - basic and diluted (2)   $ -     $ (0.07 )                
                                 
Weighted average shares outstanding - basic and diluted     19,032       19,322                  
                                 
(1)   Reflects nonrecurring charges primarily related to restructuring of the Diagnostic Imaging camera operating activities.
     
(2)   Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.
     

Investor Contact: Matt Clawson Allen & Caron 949-474-4300 Email Contact Company Contact: Jeffry Keyes CFO 858-726-1600 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 156

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 136

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 81

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 72

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 108

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Natural Hydrogen: MAX Power Mining's Vision

Updated Category News Views 184

MAX Power Mining Corp. Driving Innovation in Natural Hydrogen In an era where energy demands are escalating, especially with the rise of artificial intelligence and advanced technologies, the search for sustainable power sources has reached new heights. Enter MAX Power Mining Corp. (OTC: MAXXF) (CSE: MAXX), a trailblazer in the natural hydrogen sector, demonstrating...

Continue Reading
Inland Empire Health Plan Achieves Excellence in GIS Recognition

Updated Category News Views 246

A Celebration of Achievement for Inland Empire Health Plan Inland Empire Health Plan (IEHP) has achieved remarkable recognition by winning its third Special Achievement in GIS (SAG) award from Esri, the global leader in Geographic Information System (GIS) technology. This prestigious accolade highlights IEHP's commitment to utilizing innovative technology to enhance...

Continue Reading
Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge

Updated Category News Views 226

Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge In a groundbreaking moment for sustainable food technology, Ryp Labs was announced as the standout winner of Lineage's prestigious innovation challenge aimed at transforming the global food supply chain. The challenge focused on innovative solutions that address pressing issues such as food waste and supply...

Continue Reading
Future Landscape of the UV Stabilizers Market by 2032

Updated Category News Views 176

Growth of the UV Stabilizers Market The UV stabilizers market is gaining momentum, projected to expand from USD 1.4 billion to USD 2.3 billion by 2032, with a compound annual growth rate (CAGR) of 5.5% during the 2024-2032 period. This growth is fueled by the increasing demand for materials that are durable and can endure the degrading effects of ultraviolet (UV)...

Continue Reading
Dr. Rushika Fernandopulle Joins Premera Board of Directors

Updated Category News Views 337

Dr. Rushika Fernandopulle Joins Premera's Board Premera Blue Cross is excited to announce the addition of Dr. Rushika Fernandopulle to its Board of Directors. This decision is part of a strategic effort to strengthen leadership and expertise within the organization. Dr. Fernandopulle takes over from Dr. John Jenrette, who has completed his term this year. Expertise and...

Continue Reading